Catriona Yale Sells 6,136 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 6,136 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $30.03, for a total value of $184,264.08. Following the completion of the sale, the insider now owns 74,158 shares of the company’s stock, valued at approximately $2,226,964.74. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Catriona Yale also recently made the following trade(s):

• On Friday, September 20th, Catriona Yale sold 5,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.65, for a total value of $152,075.00.
• On Wednesday, September 18th, Catriona Yale sold 3,871 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.56, for a total value of $106,684.76.
• On Monday, September 16th, Catriona Yale sold 2,485 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.52, for a total value of $68,387.20.
• On Tuesday, September 10th, Catriona Yale sold 637 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.18, for a total transaction of $16,676.66.
• On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.53, for a total transaction of $243,668.03.
• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $143,052.00.

Akero Therapeutics Trading Up 1.3 %

Shares of Akero Therapeutics stock opened at $31.23 on Friday. The firm’s 50 day moving average is $27.36 and its 200 day moving average is $24.24. The firm has a market capitalization of $2.16 billion, a PE ratio of -9.76 and a beta of -0.25. Akero Therapeutics, Inc. has a 1 year low of $11.25 and a 1 year high of $37.00. The company has a current ratio of 24.89, a quick ratio of 24.89 and a debt-to-equity ratio of 0.04.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Friday, August 9th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.09. Equities research analysts forecast that Akero Therapeutics, Inc. will post -3.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Akero Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of AKRO. Wellington Management Group LLP raised its position in Akero Therapeutics by 247.7% in the fourth quarter. Wellington Management Group LLP now owns 2,881,989 shares of the company’s stock valued at $67,294,000 after purchasing an additional 2,053,028 shares during the last quarter. Janus Henderson Group PLC increased its stake in shares of Akero Therapeutics by 42.2% in the first quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock valued at $154,589,000 after buying an additional 1,815,569 shares during the period. Redmile Group LLC raised its holdings in Akero Therapeutics by 67.5% in the 1st quarter. Redmile Group LLC now owns 1,858,702 shares of the company’s stock valued at $46,951,000 after buying an additional 749,226 shares during the last quarter. Vanguard Group Inc. boosted its position in Akero Therapeutics by 19.0% during the 1st quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock worth $92,702,000 after buying an additional 584,875 shares during the period. Finally, Long Focus Capital Management LLC increased its position in Akero Therapeutics by 119.0% in the 2nd quarter. Long Focus Capital Management LLC now owns 719,604 shares of the company’s stock valued at $16,882,000 after acquiring an additional 391,000 shares during the period.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Akero Therapeutics in a research note on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $43.20.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.